Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the phase Ib/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma will be presented in an oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, USA, May 30-June 3, 2025. Clinical data from 3 ADC clinical studies will also be published as poster presentations at the meeting.

Oral Presentation

1. Title: 9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-naive patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a phase 1b/2 study.

Abstract Number for Publication: 4519

Presenter: Prof. Sheng Xinan, Chief Physician, Dept. of Urologic Oncology (Beijing Cancer Hospital)

Session Type and Title: Rapid Oral Abstract-Genitourinary Cancer-Kidney and Bladder

Session Date and Time:  5/31/2025, 1:15 PM-2:45 PM CDT

Poster Presentation

1. Title: Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors.

Abstract Number: 3035

Session Type and Title: Poster Session - Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology

Poster Board: 350

Session Date and Time: 6/2/2025 1:30 PM-4:30 PM CDT

2. Title: Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer.

Abstract Number: 3036

Session Type and Title: Poster Session - Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

Poster Board: 351

Session Date and Time: 6/2/2025 1:30 PM-4:30 PM CDT

3. Title: A first-in-human clinical study of 9MW2921, a novel TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Abstract Number: 3029

Session Type and Title: Poster Session - Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

Poster Board: 344

Session Date and Time: 6/2/2025 1:30 PM-4:30 PM CDT